Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study

(2022) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa

(2022) Stefan Heitmeier et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

(2021) Dirk Thomas et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Milvexian for the Prevention of Venous Thromboembolism

(2021) Jeffrey I. Weitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

(2020) Jeffrey I. Weitz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)

(2020) Gerhard Hindricks et al.   EUROPEAN HEART JOURNAL

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2019) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI

(2019) Benjamin Georgi et al.   STROKE

Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure

(2018) Gianluigi Savarese et al.   HEART

Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF

(2018) Emily C. O'Brien et al.   Journal of the American Heart Association

Antithrombotic Therapy for Atrial Fibrillation

(2018) Gregory Y.H. Lip et al.   CHEST

Factor XI as a Therapeutic TargetHighlights

(2016) David Gailani et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events

(2016) Meir Preis et al.   BLOOD

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

(2016) M Cecilia Bahit et al.   HEART

Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre

(2015) C. Santoro et al.   HAEMOPHILIA

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry

(2014) Emily C. O'Brien et al.   AMERICAN HEART JOURNAL

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2014) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Worldwide Epidemiology of Atrial Fibrillation

(2013) Sumeet S. Chugh et al.   CIRCULATION

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE